Hi N***l,
Happy to share a high-level sample milestone plan to illustrate how we benchmark IND and Phase gates. This template reflects a two-program scenario over the first 18 months:
Program A (Oncology Small Molecule)
• Months 1,3:
, Finalize CMC scale-up and GLP toxicology studies
, Pre-IND meeting with FDA (Target: Month 3)
• Months 4,6:
, File IND (Target: End of Month 6)
• Months 7,9:
, IND clearance (60‐day review window)
• Months 10,12:
, Initiate Phase 1; first patient in by Month 11
• Months 13,18:
, Complete Phase 1 safety readout (n=30); prepare Phase 2 briefing package
Program B (Rare-Disease Biologic)
• Months 1,4:
, Complete process development and nonclinical safety package
, Pre-CTA/Pre-IND alignment meetings (FDA & EMA)
• Months 5,7:
, Submit CTA to EMA and IND to FDA (Target: Month 7)
• Months 8,10:
, Regulatory clearance in both regions
• Months 11,14:
, Start combined Phase 1/2; enroll first cohort by Month 12
• Months 15,18:
, Deliver interim safety/PK readout; finalize Phase 2 protocol
Key Gates & Benchmarks
• IND/CTA clearance within target review windows
• First-patient-in timelines (±1 month tolerance)
• Phase 1 completion and safety readouts
• Protocol readiness for Phase 2
These milestones tie directly into N***n’s bonus and equity accelerators,for example, achieving IND clearance fast-track vests an extra tranche of options, and hitting Phase 1 enrollment targets unlocks bonus payouts.
Let me know if you’d like any tweaks or additional detail. Looking forward to our call Wednesday at 11 AM ET!
Best,
J***e
HR Recruiter, StrategyBrain